Oncologists want more treatment options for advanced lung cancer patients, new survey says
24 Jan 2024
Immunotherapy
Oncologists are encouraged by the number of immunotherapies to treat non-small cell lung cancer, but they still want more options, especially for advanced cases, according to a new Harris Poll survey commissioned by Regeneron and the Cancer Research InstituteCancer Research Institute.
The overwhelming majority of advanced NSCLC patients have used immunotherapy as a first-line (97%) or second-line (86%) treatment, according to the 250 oncologists surveyed, but 30% of those physicians say there’s still room for more options. Fewer than one in five oncologists rated the current options as “excellent.”
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.